Roche's experimental weekly injection enicepatide lowered blood sugar and body weight in adults with type 2 diabetes and overweight or obesity over 48 weeks, the company said Tuesday. But Roche did not release specific results for the placebo group, BioSpace reported, which makes it impossible to judge how much of the improvement came from the drug itself.
At the highest dose, 24 mg, patients' HbA1c, a measure of average blood sugar over the past two to three months, fell by 2.65 percentage points from a starting average of 8.1%. Their weight fell by an average of 15.5%, according to Roche.
